Boundless Bio (BOLD) Stock
Small cap biotech company focused on clinical trials. Here's the price, business snapshot, and what's worth knowing about Boundless Bio in October 2026.
Boundless Bio, Inc. (BOLD) is a very small-cap biotechnology company. With a market capitalisation around $33 million, it is typical of early-stage biopharma firms where value is closely tied to clinical and regulatory milestones. Investors should know this is a high-risk, high-uncertainty profile: successful trials or partnerships can materially increase value, while setbacks, funding shortfalls or regulatory delays can have the opposite effect. Financial runway, data readouts, licensing deals and strategic collaborations are common near-term catalysts. Liquidity may be limited and shares can be volatile; dilution through capital raises is a realistic possibility. This summary provides general information for educational purposes and is not personalised investment advice — anyone considering an investment should perform their own due diligence and consider their risk tolerance and investment horizon.
Boundless Bio (BOLD) Stock Forecast
Analyst price target, next 12 months
$13.00
+396.2% vs today's $2.62
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Boundless Bio have a consensus 12-month target of $13.00, above the current price of $2.62.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 28 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Boundless Bio's stock, anticipating it could rise to $13 in value.
Financial Health
Boundless Bio Inc shows solid cash flow and book value, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Milestone Catalysts
Clinical readouts, regulatory decisions and licensing deals can move the stock; however, outcomes are uncertain and can go either way.
R&D-Driven Value
Progress in research and development typically drives valuation for firms this size, but R&D timelines are long and results are not guaranteed.
Partnership Potential
Collaborations or strategic partnerships can provide funding and validation, though reliance on deals also introduces execution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
